Total: $1,142M

Ablynx NV (Ghent, Belgium)

Private placement

N/A

N/A

Ablynx conducted a private placement in Europe concurrent with an IPO of American Depositary Shares in the U.S

10/4/17

Adma Biologics Inc. (Ramsey, N.J.)

Credit facility

N/A

$30.00

Credit agreement for up to $40M with affiliated entities of Marathon Asset Management; proceeds will refinance debt with Oxford Finance LLC, pay transaction expenses and provide for working and growth capital; upon the closing, Adma received $30M of a senior secured single draw term loan, with an additional $10M senior secured single draw term loan to be provided by Marathon upon the achievement of a milestone

10/12/17

Ampio Pharmaceuticals Inc. (Englewood, Colo.)

Registered direct offering

7.7S

$6.75

$6.75M in a registered sale of common stock priced at $0.875 per share; Joseph Gunnar & Co. LLC and Forham Financial Management Inc. acted as placement agents

10/17/17

Aptose Biosciences Inc. (Toronto)

Common shares purchase agreement

N/A

$0.50

Common shares purchase agreement of up to $15.5M with Aspire Capital Fund LLC who has made an initial investment via the purchase of $500,000 of the company's common shares at $1.40 each; in addition, Aspire Capital has committed to purchase up to an additional $15 million of common shares over a 30-month period

10/31/17

Arbutus Biopharma Corp. (Vancouver, British Columbia)

Share purchase agreement

0.5S

$116.40

Signed a share purchase agreement for 500,000 convertible series A preferred shares with Roivant Sciences Inc., of New York, for gross proceeds of $116.4M

10/3/17

Arch Biopartners Inc. (Toronto)

Non-brokered, unsecured convertible note financing

N/A

$0.40

C$500,000 (US$395,000) in a note that matures on Oct. 31, 2020, and will be convertible, at the option of the holder, into common shares at $0.50 each

10/25/17

Arqule Inc. (Burlington, Mass.)

Private placement

13.9S and 3.1W

$15.70

$15.7M through the private placement led by BVF Partners LP, involving 13.9M shares of common stock and about 3.1M warrants

10/17/17

Asterias Biotherapeutics Inc. (Fremont, Calif.)

Registered direct offering

4S

$10.40

$10.4M in a registered direct offering of 4M shares of series A common stock at an offering price of $2.60 per share; Chardan acted as the sole placement agent

10/17/17

Auris Medical Holding AG (Zug, Switzerland)

Share purchase agreement

N/A

$15.00

$15M from Lincoln Park Capital Fund LLC (LPC), a Chicago-based institutional investor

10/12/17

Biophytis SA (Paris)

Private placement

N/A

$12.30

€10.4M (US$12.3M) capital raise via the issuance of new ordinary shares without shareholders' preferential subscription rights and reserved to institutional investors in Europe and the U.S.

10/12/17

CASI Pharmaceuticals Inc. (Rockville, Md.)

Registered direct offering

N/A

$23.80

$23.8M through certain institutional and accredited investors, including existing shareholders; the company has agreed to sell approximately 7.95M shares of its common stock and warrants to purchase shares of its common stock; each unit, consisting of one share of common stock and a warrant to purchase 0.2 share of common stock will be sold for a purchase price of $3; the warrants will become exercisable six months after the issuance date and have a term of 2.5 years and an exercise price equal to $3.75

10/16/17

Cellectar Biosciences Inc. (Madison, Wis.)

Registered direct offering

4.1S and W for 3.1S

$7.76

$7.76M through the sale of 4.1M shares of common stock and warrants to purchase about 3.1M shares, at an offering price of $1.87375 per share and related warrant; Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent

10/11/17

Celsion Corp. (Lawrenceville, N.J.)

Exercise of warrants

2.4W

$15.60

$15.6M through securities purchase agreement with certain investors pursuant to which the company agreed, among other things, to issue 2.4M series AAA warrants at an exercise price of $2.07 per share and 2.4M series BBB warrants at an exercise price of $4.75 per share, each to purchase one share of common stock of the company to such investors in a private placement

10/6/17

Cidara Therapeutics Inc. (San Diego)

Private placement of common stock

3.36S

$20.00

$20M through a private placement of 3.36M shares of common stock at $6 per share; investors were Great Point Partners LLC, BB Biotech AG, Prosight Capital, Broadfin Capital LLC and certain other institutional investors; Cantor Fitzgerald & Co. acted as sole placement agent

10/20/17

Critical Outcome Technologies Inc. (London)

Nonbrokered private placement

0.48U

$0.45

C$560,000 (US$449,400) through a private placement of 482,686 units at C$1.16 per unit; a unit consists of one share and one warrant to buy another share at C$1.21 per share for a period of 12 months from the date of issue; this is the second tranche of a C$2M (US$1.6M) private placement announced Sept. 20

10/19/17

Emergent Biosolutions Inc. (Gaithersburg, Md.)

Senior secured credit facility

N/A

(up to $200)

Five-year, $200M syndicated senior secured credit facility, which replaces and represents an increase from the previous $100M facility, which was scheduled to expire in December 2018

10/3/17

Faron Pharmaceuticals Oy (Turku, Finland)

Private placement

1.1S

$11.55

£10M ($11.55M) through the placing of 1.1M shares and a proposed subscription of up to 126,250 new ordinary shares at 800 pence (US$10.50) per share; Panmure Gordon (U.K.) Ltd. is acting as sole bookrunner and corporate broker

10/6/17

Genfit SA (Lille, France)

Private placement

N/A

$213.30

Offering of bonds convertible into new shares and/or exchangeable for existing shares due Oct. 16, 2022, by way of a private placement to institutional investors for €180M (US$213.3M)

10/2/17

Genfit SA (Lille, France)

Private placement

Bonds

$211.50

Settled its offering of bonds convertible into new shares and/or exchangeable for existing shares due Oct. 16, 2022, by way of a private placement to institutional investors for a nominal amount of €180M (US$211.5M)

10/18/17

Helix Biopharma Corp. (Toronto)

Private placement

Units

$3.09

C$3.9M (US$3.09M) for the purchase of units at $1.20 each; each unit is comprised of one common share and one common share purchase warrant that will entitle the holder to purchase one common share at an exercise price of $1.50

10/23/17

Herantis Pharma plc (Espoo, Finland)

Private placement

0.8S

$5.40

€4.6M (US$5.4M) through a new share issue of up to 800,000 shares

10/20/17

Intellipharmaceutics International Inc. (Toronto)

Registered direct offering

3.6S

$4.00

$4M through the sale of 3.6M common shares at $1.10 per share and unregistered warrants to purchase an aggregate of 1.8M common shares at $1.25 per share

10/12/17

Intrexon Corp. (Germantown, Md.)

Preferred stock equity facility

N/A

(up to $100)

Entered a preferred stock equity facility with an affiliate of Third Security LLC, a venture capital firm founded by Randal J. Kirk, Intrexon's chairman and CEO; under the facility, Intrexon may, at its discretion, sell to the investor up to $100M of newly issued series A redeemable preferred stock

10/18/17

Mabvax Therapeutics Holdings Inc. (San Diego)

Private placement

0.769S

$0.50

Agreed to sell 769,231 shares of its common stock at 65 cents each for gross proceeds of about $500,000 to certain accredited investors

10/12/17

Mannkind Corp. (Westlake Village, Calif.)

Registered direct offering

10.1S

$61.00

$61M through the offering of 10.1M shares at $6 each; H.C. Wainwright & Co. is acting as the exclusive placement agent

10/12/17

Myovant Sciences Ltd. (Basel, Switzerland)

Private placement and loan

N/A

$140.00

$140M in flexible financing commitments from Novaquest Capital Management and Hercules Capital Inc.; the Novaquest financing comprises a note purchase commitment of up to $60M and an equity purchase commitment of up to $40M; an additional $40M of debt financing is committed in a term loan facility from Hercules

10/17/17

Nexstim plc (Helsinki, Finland)

Private placement

7S

$2.07

€1.75M (US$2.07M) through a London-based fund managed by City Financial Investment Co. Ltd.; involves up to 7M new shares at a subscription price of €0.25 per share

10/26/17

Obseva SA (Geneva)

Private placement of common shares and prepaid warrants

N/A

$60.00

$60M through the sale of common shares and prepaid warrants to a group of institutional accredited investors

10/11/17

Oncosec Medical Inc. (San Diego)

Registered direct offering

5.27S and W for 3.95S

$7.10

$7.1M through certain accredited investors who purchased 5.27M shares of its common stock at $1.34375 and issued unregistered warrants to purchase up to 3.95M shares of common stock at $1.25 per share for a term of 5.5 years

10/24/17

Pluristem Therapeutics Inc. (Haifa, Israel)

Private placement

8.87S

$15.00

Concluded an Israeli institutional investors tender in which the company received overall commitments from Israeli institutional investors and accredited investors for the purchase of 8.87M shares in different prices for a total amount of approximately $15M

10/31/17

Prometic Life Sciences Inc. (Laval, Quebec)

Credit facility

10W and 44W

(up to $80)

Entered into a binding letter of intent to secure an $80M (C$100M) line of credit from Structured Alpha LP, an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc.; the first two tranches can be drawn within 15 days of closing, with each additional tranche becoming available on a monthly basis thereafter; any amount drawn down will bear interest of 8.5% per annum and will be repayable within two years; Prometic will grant Structured Alpha an initial 10M warrants with an exercise price of C$1.70 per common share with a term expiring June 30, 2026, alongside an additional 44M warrants at the same exercise price and term, which will vest in tranches each time Prometic draws an additional amount of $10M (C$12.5M) under the facility

10/24/17

Relmada Therapeutics Inc. (New York)

Private placement of convertible promissory notes and warrants

N/A

$6.90

$6.9M in 7% convertible promissory notes, with a two-year term that automatically converts into common stock in a future equity financing, and 4.6M seven-year warrants exercisable at $1.50 per share; Alexander Capital LP acted as exclusive placement agent

10/6/17

Replicel Life Sciences Inc. (Vancouver, British Columbia)

Private placement

2.81S

$1.15

$1.15M in a non-brokered private placement of 2.81M shares at $0.41 each

10/23/17

Resverlogix Corp. (Calgary)

Private placement

60U

$18.20

$18.2M in a private placement that raised $87M, with proceeds paying off a loan of $68.8M; a total of 60M equity units were sold to Shenzhen Hepalink Pharmaceutical Co. Ltd. at $1.44 each

10/16/17

Rexahn Pharmaceuticals Inc. (Rockville, Md.)

Private placement of common stock and warrants

3.27S and W for 1.63S

$8.00

$8M through definitive agreements with institutional investors to purchase approximately 3.27M shares of its common stock and warrants exercisable for up to approximately 1.63M shares of its common stock

10/16/17

Sirona Biochem Corp. (Vancouver, British Columbia)

Non-brokered private placement

3.56U

$0.54

$535,000 through a placement of 3.56M units at $0.15 each; each unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the company for a period of two years from the date of issue at $0.25 per share

10/26/17

Supreme Pharmaceuticals Inc. (Toronto)

Private placement of convertible debenture units

Units

$35.00

$35M in a bought deal agreement with Canaccord Genuity Corp.

10/19/17

Syndax Pharmaceuticals Inc. (Waltham, Mass.)

Registered direct offering

2S

$25.00

$25M through the sale of 2M shares of common stock to Biotechnology Value Fund LP and certain of its affiliates based on the offering price of $12.37 per share; BTIG LLC served as a capital markets advisor

10/18/17

VBI Vaccines Inc. (Cambridge, Mass.)

Registered direct offering

7.47S

$22.80

$22.8M through the registered direct offering of 7.47M shares at $3.05 each, which is in addition to $49.1M raised in an underwritten public offering of 16.1M shares at the same price; total proceeds were $71.9M

10/27/17

Viking Therapeutics Inc. (San Diego)

Common stock purchase agreement

N/A

$15.00

$15M common stock purchase agreement with Lincoln Park Capital Fund LLC; under a separate purchase agreement, LPC has agreed to purchase $1.25M of Viking's registered common stock at $1.78 per share

10/2/17

Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.